October 15, 2020
Yourgene Health plc
(“Yourgene” or the “Group” or the “Company”)
IONA® Nx awarded contract with St George’s NHS Hospital
Manchester, UK – 7 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has been awarded the contract for non-invasive prenatal testing (NIPT) using its newly-launched IONA® Nx NIPT Workflow (‘IONA® Nx’), by the prestigious St George’s NHS Trust Foundation in Tooting, South London (“St George’s”). The contract, subject to signing by both parties, has been awarded after a competitive tender process and will extend Yourgene’s existing partnership with St George’s for a further three years, with testing volumes expected to increase over the contract period.
St George’s was the first NIPT NHS laboratory in the UK and the first NHS Trust to provide NIPT testing to high risk pregnant women. St George’s has a reputation for innovation in NIPT introducing these tests well ahead of the National Screening committee’s January 2016 recommendation to do so. Yourgene won its first tender with St George’s on 23 March 2015 with the Company’s IONA® test to provide NIPT testing for women within South East England and to other NHS trusts and private practices across the UK.
Since that first tender, the lab has been offering the IONA® test under the St George’s brand of the SAFE test. The new contract will see St George’s transition over to the IONA® Nx NIPT Workflow which has been developed to run on the Illumina NextSeq 550Dx instrument.
Lyn Rees, CEO of Yourgene, commented: “We were chosen out of five companies that bid for the tender; I believe this is a true reflection of the excellent service and continued support that Yourgene offers its customers. The team at St George’s have been early adopters and true champions of the benefits of NIPT for all pregnant women as part of antenatal screening. We have already been working in close partnership with St George’s over the last few years, and look forward to strengthening our relationship with them further over the next few years.”
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Yourgene Health plc
Lyn Rees, Chief Executive Officer
Tel: +44 (0)161 669 8122
|Cairn Financial Advisers LLP (NOMAD)|
Liam Murray / James Caithie / Ludovico Lazzaretti
|Tel: +44 (0)20 7213 0880|
|N+1 Singer (Joint Corporate Broker)|
Aubrey Powell / Tom Salvesen / George Tzimas
|Tel: +44 (0)20 7496 3000|
Stifel Nicolaus Europe Limited (Joint Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben Maddison
Tel: +44 (0)20 7710 7600
Walbrook PR Ltd (Media and Investor Relations)
Paul McManus / Lianne Cawthorne
Tel: +44 (0)20 7933 8780 or email@example.com
Mob: 07980 541 893 Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group’s products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene’s commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
About Coastal Genomics
The “Why” behind Coastal Genomics is that good science should not hinge on the fickle nature of manual bench science. This is a shared perspective as evidenced by the continued move to automate life science protocols. Techniques that compromise on result quality in exchange for automatability can be a viable option for some workflows. Inevitably though, the demands of new applications that are high value and high throughput in nature come to require high quality input that can only be delivered by golden standard bench techniques. Please visit our website at www.coastalgenomics.com to learn more about how we help secure quality sample preparation.